PEG/PG with HPG Lubricating Eye Drops for Treating Dry Eye due to CVS
Introduction
Computer vision syndrome (CVS), a result of prolonged exposure to various digital displays has a varied prevalence, predominating typically among office goers and students. CVS is characterized by a group of visual, ocular, and muscular symptoms and usually develops due to >3 h/day or >30 h/week use of a computer. The development of dry eye disease (DED) is the primary symptom of CVS. DED due to CVS is primarily treated with artificial tear supplements. Polyethylene glycol/propylene glycol with hydroxypropyl guar (PEG/PG with HPG) lubricating eye drops have been available for long time for the treatment of DED. Studies till date have demonstrated PEG/PG-HPG to be effective and safe in improving DED.
Aim
To determine the clinical effectiveness and safety of PEG/PG with HPG for treating computer vision syndrome (CVS)-related dry eye.
Patient Profile
- Adult patients (age ≥18 years), with a TFBUT of ≤10 s in at least one eye, and best-corrected visual acuity (BCVA) of ≥20/80 (or ≥55 letters score or ≥0.6 early treatment diabetic retinopathy study log of the minimum angle of resolution value).
- The patients who met at least one of the three following criteria in at least one eye at screening were also eligible for inclusion in study
- Unanesthetized Schirmer I test score of ≤9 mm for a 5-min test duration (aqueous deficient dry eye stratum)
- Meibum quality score of ≥1 (on a 0–3 scale) or meibum expressibility score of >1 (on a 0–3 scale) in either eyelid (evaporative dry eye stratum)
- Met both entry criteria (a) and (b) (mixed dry eye stratum)
- All eligible patients had daily computer/visual display unit (VDU) use >3 h/day/15 h/week, with a minimum of 3 months of exposure to any VDU and with CVS questionnaire (CVS-Q) score ≥6, and OSDI Score 23–32 (both inclusive) with dry eye symptoms.
Methods
Study Design
- A prospective, single-arm, single-center, interventional study.
Treatment Strategy
- The study subjects received the first dose of PEG/PG with HPG on day 1, the eye drops were self-administered 4 times daily for 30 days. Follow-up visits were scheduled on day 15 and day 30.
- Additional doses of the study medication could be administered as required, in case patients experienced any dry eye symptoms.
Outcomes
Primary Outcome
- Change in ocular surface disease index (OSDI) from baseline to end of the study
Exploratory Outcome
- The percentage of patients with a reduction of >4.5 in OSDI score during the study
Secondary Outcome
- Mean changes in tear film break-up time (TFBUT) and CVS questionnaire (CVS-Q).
Results
- The study population comprised of 60 patients, median age of the study population was 23 years.
- The mean OSDI reduced significantly (P < 0.0001) on day 15 and day 30 from baseline (−3.8 on day 15 and −9.6 on day 30) (Fig. 1).
Fig. 1: Reduction in OSDI score from baseline to end of the study period
- Nearly one-third of the study population (36.36%) reported a reduction of >4.5 in OSDI scores following 2 weeks of PEG/ PG with HPG treatment. By the end of the study, most of the patients (86.36%) had achieved a reduction of >4.5 in OSDI scores
- The TFBUT changed significantly from the baseline (intragroup) to subsequent visits (Day 15: Mean [SD] – 1.2 [3.15], P = 0.0081; Day 30: 1.3 [2.35], P < 0.0001).
- The mean (SD) CVS-Q scores improved significantly from baseline to both the follow-up points (mean [SD], baseline: 10 [1.89], day 15: −2.5 [2.01], day 30: −5.7 [2.29], and all P < 0.0001).
- No adverse events (AEs) were reported during the study.
Conclusions
- A short-term treatment with PEG/PG with HPG was effective for treating dry eye symptoms associated with CVS.
- No new safety concerns emerged during this study.
Clin Exp Vis Eye Res. 2023;6:8-13.









